Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

NCT01615198 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

588

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Olmesartan
DRUG: Placebo
DRUG: LCZ696

Sponsor

Novartis Pharmaceuticals